Retraction: Chronically high level of  tgfb1a  induction causes both hepatocellular carcinoma and cholangiocarcinoma via a dominant Erk pathway in zebrafish

Chuan Yan; Qiqi Yang; Han-Ming Shen; Jan M. Spitsbergen; Zhiyuan Gong

doi:10.18632/oncotarget.28570

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction: Chronically high level of tgfb1a induction causes both hepatocellular carcinoma and cholangiocarcinoma via a dominant Erk pathway in zebrafish

PDF | How to cite

Oncotarget. 2024; 15:301-301. https://doi.org/10.18632/oncotarget.28570

Metrics: PDF 614 views | ?

Chuan Yan^1,2, Qiqi Yang¹, Han-Ming Shen³, Jan M. Spitsbergen⁴ and Zhiyuan Gong^1,2

¹Department of Biological Sciences, National University of Singapore, Singapore
²National University of Singapore Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore
³Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
⁴Department of Microbiology, Oregon State University, Corvallis, OR, USA

Published: May 14, 2024

Copyright: © 2024 Yan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Multiple figure images in this paper were found to contain internal overlaps and duplications. Specifically, duplicate images were discovered in Figures 1B, 4A, 4B and 5C. The authors were unable to make corrections using the original data. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.

Original article: Oncotarget. 2017; 8:77096–77109. DOI: https://doi.org/10.18632/oncotarget.20357

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28570

Publication Alerts

Post-Publication Promotion

Publication Discount

Retraction:

Retraction: Chronically high level of tgfb1a induction causes both hepatocellular carcinoma and cholangiocarcinoma via a dominant Erk pathway in zebrafish